Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more
Tvardi Therapeutics, Inc. (TVRD) - Total Assets
Latest total assets as of September 2025: $39.02 Million USD
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) holds total assets worth $39.02 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tvardi Therapeutics, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tvardi Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tvardi Therapeutics, Inc.'s total assets of $39.02 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.5% |
| Accounts Receivable | $4.50 Million | 10.3% |
| Inventory | $900.00K | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tvardi Therapeutics, Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 71.9% in 2020.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2024, up from 11.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
Tvardi Therapeutics, Inc. Competitors by Total Assets
Key competitors of Tvardi Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tvardi Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tvardi Therapeutics, Inc. generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tvardi Therapeutics, Inc. is currently not profitable relative to its asset base.
Tvardi Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.48 | 4.77 | 4.40 |
| Quick Ratio | 3.48 | 4.71 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.40 Million | $ 37.87 Million | $ 77.72 Million |
Tvardi Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Tvardi Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 62.3% |
| Total Assets | $43.83 Million |
| Market Capitalization | $31.80K USD |
Valuation Analysis
Below Book Valuation: The market values Tvardi Therapeutics, Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tvardi Therapeutics, Inc.'s assets grew by 62.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual total assets of Tvardi Therapeutics, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.83 Million | +62.32% |
| 2023-12-31 | $27.00 Million | -40.13% |
| 2022-12-31 | $45.10 Million | -81.75% |
| 2021-12-31 | $247.06 Million | -8.89% |
| 2020-12-31 | $271.16 Million | -- |